# A billion-dollar prize for the first durable cure of a lethal metastatic cancer

Source: https://onco.cc/ideas/idea-fund-cure-prize/  
OnCo record `idea-fund-cure-prize` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Governments and foundations would pool a prize of about a billion dollars into an escrowed fund, paid only when a treatment is shown in a well-controlled registration cohort to keep most patients with a currently incurable metastatic cancer, such as pancreatic adenocarcinoma or glioblastoma, disease-free for five years. The winner keeps its patent but accepts a price ceiling.

## Summary

A pull incentive that pays for the outcome the system currently under-rewards. The prize is defined in advance per disease (for example metastatic pancreatic adenocarcinoma, glioblastoma, metastatic TNBC) with an objective bar such as at least 50% five-year disease-free survival in a randomised or well-controlled registration cohort where the historical figure is under 5%. The winner keeps its patent but accepts a price ceiling and global access licensing as a condition. Multiple sponsors could pool into a single escrowed fund; a partial prize could be paid for intermediate milestones (for example 25% durable remission).

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A credible, escrowed cure prize of one billion dollars or more per disease increases the number of registered first-in-class programmes in the named diseases by at least half within five years and attracts new entrants (academic spin-outs, non-oncology companies) that the current market does not.
- Rationale: Pull mechanisms have worked where the goal is well-specified and the market signal weak: the Ansari X Prize, the Longitude Prize, Gavi's advance market commitment and DARPA challenges. Current oncology rewards are indifferent to magnitude of benefit, so capital flows to predictable incremental gains; a prize inverts the payoff curve for the hardest problems.
- Proposed test: Announce a single-disease prize with a fully escrowed fund and pre-registered success criteria, then track new programme registrations, venture funding and phase 1 starts in that disease against matched diseases without a prize over five years.
- Maturity: speculative
- Actor: policy

## Sources

- XPRIZE: https://www.xprize.org/
- Longitude Prize: https://longitudeprize.org/

## Connected records

- ideas: [Milestone prizes for first-in-class mechanisms reaching human proof of concept](https://onco.cc/ideas/idea-fund-first-in-class-prize/), [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/), [Prizes for unpatentable surgical and radiotherapy techniques proven in trials](https://onco.cc/ideas/idea-fund-technique-innovation-prize/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-cure-prize.json